Stage-specific prognostic biomarkers in melanoma

摘要: // Yabin Cheng 1 , Jing Lu 2 Guangdi Chen 3 Gholamreza Safaee Ardekani Anand Rotte Magdalena Martinka 4 Xuezhu Xu 5 Kevin J. McElwee Guohong Zhang 1, 6 Youwen Zhou Department of Dermatology and Skin Science, Vancouver Coastal Health Research Institute, University British Columbia, Vancouver, Canada Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China Bioelectromagnetics Laboratory, Zhejiang School Medicine, Hangzhou, Zhejiang, Pathology, Dermatology, Second Affiliated Hospital, Dalian Dalian, Shantou Shantou, Guangdong, Correspondence to: Zhou, e-mail: Youwen.Zhou@vch.ca Zhang, gghzhang@gmail.com Keywords: prognostic biomarker, stage-specific, melanoma, BRAF, MMP2 Received: September 25, 2014      Accepted: December 13, Published: January 10, 2015 ABSTRACT The melanoma staging system proposed by the American Joint Committee on Cancer (AJCC) (which classifies patients into four clinical stages) is currently most widely used tool for prognostication, management decision making clinicians. However, multiple studies have shown that melanomas within specific AJCC Stages can exhibit varying progression outcomes. Thus, additional information, such as provided biomarkers needed to assist in identifying at risk disease progression. Having previously found six independent including MMP2, p27, Dicer, Fbw7 Tip60, our group has gone investigate if these markers are useful stratification individual stages. First, we performed Kaplan-Meier survival Cox proportional multivariate analyses comparing prognostication power 254 whom expression levels were known, best performing candidates stage-specific markers. We then verified results incorporating an cohort (87 patients) a combined (341 patients). Our data indicate BRAF optimal I II, respectively ( P = 0.010, 0.000, Log-rank test); whereas p27 emerged good marker III/IV (0.018, 0.046, respectively, log-rank test). study identified finding which may clinicians designing improved personalized therapeutic modalities.